Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2020/12/029575
CTRI/2020/12/029575
Not yet recruiting
Phase 3

A study to assess the safety and efficacy of add-on Unani regimen in preventing the progression of severity of the disease in mild to moderate symptomatic COVID-19 RT-PCR positive cases

Central Council for Research in Unani Medicine0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: J09- Influenza due to certain identified influenza viruses

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: J09- Influenza due to certain identified influenza viruses
Sponsor
Central Council for Research in Unani Medicine
Status
Not yet recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. On the day of admission patients who have been tested positive with SARS\-CoV2 virus through RT PCR
  • •2\. Patients with mild symptoms
  • •Patients with moderate symptoms with respiratory rate \< 30 per minute and oxygen saturation \> 90%

Exclusion Criteria

  • •1\.COVID\-19 patients with symptoms classified as severe or critical.
  • •2\.Suspected COVID\-19, not tested positive for COVID\-19 by RT\-PCR
  • •3\.Persons with severe primary respiratory disease or pneumonia
  • •4\.Pregnant and lactating women
  • •5\.Persons with severe illness such as Cancer, Heart Disease, Stroke, Mental disorder, etc., and who are considered to be excluded from the study as evaluated by the Investigators
  • •6\.COVID\-19 positive cases simultaneously participating as subjects in the interventional arm of other COVID\-19 clinical trials

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Investigation of efficacy and safety of add-on therapy with DPP-4 inhibitor in type 2 diabetic patients poorly controlled with basal supported oral therapyType 2 diabetes
JPRN-UMIN000010849Department of Metabolism &amp; Endocrinology Juntendo University Graduate School of Medicine40
Recruiting
Phase 2
Evaluation of the efficacy and safety of lacosamide to duloxetine in the treatment of taxanes- induced peripheral neuropathyTaxane-induced neuropathy.
IRCT20090613002027N21Mazandaran University of Medical Sciences60
Completed
Phase 2
Olanzapine as a medication to reduce nausea and vomiting following chemotherapy in childrePalliative care.Encounter for palliative care
IRCT20090613002027N14Sari University of Medical Sciences49
Active, not recruiting
Not Applicable
A trial, in which subjects with type 2 diabetes, who qualify for treatment intensification, are given insulin degludec and, additionally, either liraglutide or insulin aspart, both in combination with metformin, with the largest meal. The purpose is to compare efficacy and safety of these two treatments.
EUCTR2011-001493-25-ATovo Nordisk A/S420
Active, not recruiting
Not Applicable
A trial, in which subjects with type 2 diabetes, who qualify for treatment intensification, are given insulin degludec and, additionally, either liraglutide or insulin aspart, both in combination with metformin, with the largest meal. The purpose is to compare efficacy and safety of these two treatments.Type 2 diabetesMedDRA version: 14.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2011-001493-25-DEovo Nordisk A/S420